Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

Roman Gulati, Angela B. Mariotto, Shu Chen, John L. Gore, Ruth Etzioni

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States. Study Design and Setting: A mathematical model of disease-specific deaths in screened and unscreened men given information on overdiagnosis, disease-specific survival in the absence of screening, screening efficacy, and other-cause mortality is presented. A simulation framework is used to incorporate competing causes of death. Results: Assuming overdiagnosis and screening efficacy consistent with European Randomized study of Screening for Prostate Cancer (ERSPC) results, we project that, after 25 years, 262 men need to be screened and nine additional men need to be screen detected to prevent one prostate cancer death. Corresponding estimates of the NNS and the additional NNT under a range of overdiagnosis rates that are consistent with U.S. incidence are 186-220 and 2-5. Conclusions: Long-term estimates of the NNS and the additional NNT are an order of magnitude lower than the short-term estimates published with the results of the ERSPC trial and may be consistent with cost-effective PSA screening in the general U.S. population.

Original languageEnglish (US)
Pages (from-to)1412-1417
Number of pages6
JournalJournal of Clinical Epidemiology
Volume64
Issue number12
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Early Detection of Cancer
Numbers Needed To Treat
Prostatic Neoplasms
Prostate-Specific Antigen
Cause of Death
Theoretical Models
Costs and Cost Analysis
Survival
Mortality
Incidence
Population
Medical Overuse

Keywords

  • Cost-benefit analysis
  • Mass screening
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Simulation modeling
  • Treatment efficacy

ASJC Scopus subject areas

  • Epidemiology

Cite this

Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. / Gulati, Roman; Mariotto, Angela B.; Chen, Shu; Gore, John L.; Etzioni, Ruth.

In: Journal of Clinical Epidemiology, Vol. 64, No. 12, 01.12.2011, p. 1412-1417.

Research output: Contribution to journalArticle

Gulati, Roman ; Mariotto, Angela B. ; Chen, Shu ; Gore, John L. ; Etzioni, Ruth. / Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. In: Journal of Clinical Epidemiology. 2011 ; Vol. 64, No. 12. pp. 1412-1417.
@article{d44662a20fd04576a7a85158625849a4,
title = "Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates",
abstract = "Objective: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States. Study Design and Setting: A mathematical model of disease-specific deaths in screened and unscreened men given information on overdiagnosis, disease-specific survival in the absence of screening, screening efficacy, and other-cause mortality is presented. A simulation framework is used to incorporate competing causes of death. Results: Assuming overdiagnosis and screening efficacy consistent with European Randomized study of Screening for Prostate Cancer (ERSPC) results, we project that, after 25 years, 262 men need to be screened and nine additional men need to be screen detected to prevent one prostate cancer death. Corresponding estimates of the NNS and the additional NNT under a range of overdiagnosis rates that are consistent with U.S. incidence are 186-220 and 2-5. Conclusions: Long-term estimates of the NNS and the additional NNT are an order of magnitude lower than the short-term estimates published with the results of the ERSPC trial and may be consistent with cost-effective PSA screening in the general U.S. population.",
keywords = "Cost-benefit analysis, Mass screening, Prostate-specific antigen, Prostatic neoplasms, Simulation modeling, Treatment efficacy",
author = "Roman Gulati and Mariotto, {Angela B.} and Shu Chen and Gore, {John L.} and Ruth Etzioni",
year = "2011",
month = "12",
day = "1",
doi = "10.1016/j.jclinepi.2011.06.011",
language = "English (US)",
volume = "64",
pages = "1412--1417",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "12",

}

TY - JOUR

T1 - Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

AU - Gulati, Roman

AU - Mariotto, Angela B.

AU - Chen, Shu

AU - Gore, John L.

AU - Etzioni, Ruth

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Objective: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States. Study Design and Setting: A mathematical model of disease-specific deaths in screened and unscreened men given information on overdiagnosis, disease-specific survival in the absence of screening, screening efficacy, and other-cause mortality is presented. A simulation framework is used to incorporate competing causes of death. Results: Assuming overdiagnosis and screening efficacy consistent with European Randomized study of Screening for Prostate Cancer (ERSPC) results, we project that, after 25 years, 262 men need to be screened and nine additional men need to be screen detected to prevent one prostate cancer death. Corresponding estimates of the NNS and the additional NNT under a range of overdiagnosis rates that are consistent with U.S. incidence are 186-220 and 2-5. Conclusions: Long-term estimates of the NNS and the additional NNT are an order of magnitude lower than the short-term estimates published with the results of the ERSPC trial and may be consistent with cost-effective PSA screening in the general U.S. population.

AB - Objective: To project long-term estimates of the number needed to screen (NNS) and the additional number needed to treat (NNT) to prevent one prostate cancer death with prostate-specific antigen (PSA) screening in Europe and in the United States. Study Design and Setting: A mathematical model of disease-specific deaths in screened and unscreened men given information on overdiagnosis, disease-specific survival in the absence of screening, screening efficacy, and other-cause mortality is presented. A simulation framework is used to incorporate competing causes of death. Results: Assuming overdiagnosis and screening efficacy consistent with European Randomized study of Screening for Prostate Cancer (ERSPC) results, we project that, after 25 years, 262 men need to be screened and nine additional men need to be screen detected to prevent one prostate cancer death. Corresponding estimates of the NNS and the additional NNT under a range of overdiagnosis rates that are consistent with U.S. incidence are 186-220 and 2-5. Conclusions: Long-term estimates of the NNS and the additional NNT are an order of magnitude lower than the short-term estimates published with the results of the ERSPC trial and may be consistent with cost-effective PSA screening in the general U.S. population.

KW - Cost-benefit analysis

KW - Mass screening

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Simulation modeling

KW - Treatment efficacy

UR - http://www.scopus.com/inward/record.url?scp=80055019354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055019354&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2011.06.011

DO - 10.1016/j.jclinepi.2011.06.011

M3 - Article

C2 - 22032753

AN - SCOPUS:80055019354

VL - 64

SP - 1412

EP - 1417

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 12

ER -